2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
545
Squamous Cell Carcinoma of Head and Neck
281
Head and Neck Neoplasms
258
Lung Neoplasms
240
Uterine Cervical Neoplasms
182
Stomach Neoplasms
172
Esophageal Neoplasms
161
Nasopharyngeal Carcinoma
127
Urinary Bladder Neoplasms
117
Esophageal Squamous Cell Carcinoma
116
Neoplasms
115
Small Cell Lung Carcinoma
106
Ovarian Neoplasms
92
Breast Neoplasms
92
Neoplasm Metastasis
90
Cholangiocarcinoma
77
Carcinoma, Squamous Cell
76
Pancreatic Neoplasms
73
Biliary Tract Neoplasms
72
Oropharyngeal Neoplasms
57
Mesothelioma, Malignant
57
Carcinoma
55
Adenocarcinoma Of Esophagus
52
Recurrence
48
Parkinson Disease 4, Autosomal Dominant Lewy Body
47
Carcinoma, Ovarian Epithelial
46
Nasopharyngeal Neoplasms
41
Lymphoma
41
Adenocarcinoma of Lung
41
Triple Negative Breast Neoplasms
39
Interventions
Immunotherapy
1
Gemcitabine
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unresectable Biliary Tract Cancer
×
Cisplatin
×
Clear all
NCT02632305
2025-06-26
AX-CSARC
AHS Cancer Control Alberta
Phase 2
Active not recruiting
45 enrolled